At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MRNY YieldMax MRNA Option Income Strategy ETF
Market Closed 10-30 16:00:00 EDT
40.74
-0.26
-0.63%
盘后40.60
-0.14-0.34%
19:56 EDT
High41.50Low40.12Vol171.89K
Open40.74D1 Closing41.00Amplitude3.37%
Mkt Cap238.53MTradable Cap238.53MTotal Shares5.85M
T/O6.99MT/O Rate2.94%Tradable Shares5.85M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

AstraZeneca’s $80 Billion Ambition Comes With a $2 Billion Reset
Bellwether Stocks Movement  ·  10-30 22:42
AstraZeneca’s $80 Billion Ambition Comes With a $2 Billion Reset
Astrazeneca shares jump as it kicks off $2bn drug pipeline investment
cityam  ·  10-30 18:03
Astrazeneca shares jump as it kicks off $2bn drug pipeline investment
Moderna’s Next‑Gen Pediatric Covid Shot Enters Key Phase 2 Test: What Investors Should Watch
TIPRANKS  ·  10-30 00:31
Moderna’s Next‑Gen Pediatric Covid Shot Enters Key Phase 2 Test: What Investors Should Watch
Can Merck Replace The World’s Biggest Cancer Drug?
Bellwether Stocks Movement  ·  10-29 22:36
Can Merck Replace The World’s Biggest Cancer Drug?
Moderna CEO Says for Germany and Europe, Launch of Skin Cancer Drug in 2028 is a Possibility - Wiwo
THOMSON REUTERS  ·  10-29 17:16
Moderna CEO Says for Germany and Europe, Launch of Skin Cancer Drug in 2028 is a Possibility - Wiwo
Here's Why Moderna's CEO Isn't Fazed by Its Cancer-Vaccine Selloff
Dow Jones  ·  10-29
Here's Why Moderna's CEO Isn't Fazed by Its Cancer-Vaccine Selloff
Moderna (MRNA) Gets Phase 3 Melanoma Win With Survival Gains Published In NEJM
Simply Wall St.  ·  10-29
Moderna (MRNA) Gets Phase 3 Melanoma Win With Survival Gains Published In NEJM
Moderna’s Next Flu Move: New Pediatric mRNA-1010 Trial Targets Long-Term Vaccine Growth
TIPRANKS  ·  10-29
Moderna’s Next Flu Move: New Pediatric mRNA-1010 Trial Targets Long-Term Vaccine Growth
Option traders moderately bearish in Moderna with shares up 2.24%
TIPRANKS  ·  10-28
Option traders moderately bearish in Moderna with shares up 2.24%
Moderna Publishes Presentation on Intismeran Phase 3 Melanoma Study
Reuters  ·  10-27
Moderna Publishes Presentation on Intismeran Phase 3 Melanoma Study
Moderna falls -7.7%
TIPRANKS  ·  10-27
Moderna falls -7.7%
Moderna Stock (MRNA) Falls 3% as Analysts Question $80 Billion Valuation Despite CEO’s Defense of Cancer Vaccine
TIPRANKS  ·  10-27
Moderna Stock (MRNA) Falls 3% as Analysts Question $80 Billion Valuation Despite CEO’s Defense of Cancer Vaccine
Moderna Has Its Doubters. CEO Bancel Plans to Answer with a Cancer Shot.
Dow Jones  ·  10-27
Moderna Has Its Doubters. CEO Bancel Plans to Answer with a Cancer Shot.
William Blair Initiates Moderna at Market Perform
MT Newswires Live  ·  10-27
William Blair Initiates Moderna at Market Perform
Moderna : William Blair Cuts to Market Perform from Outperform
THOMSON REUTERS  ·  10-27
Moderna : William Blair Cuts to Market Perform from Outperform
Dow Jones Top Company Headlines at 5 am ET: Nvidia to Invest $3 Billion in Meta's Equity Offering | Novartis ...
Dow Jones  ·  10-27
Dow Jones Top Company Headlines at 5 am ET: Nvidia to Invest $3 Billion in Meta's Equity Offering | Novartis ...
Moderna CEO Seeks to Reassure Investors on Cancer Vaccine’s Wider Potential
Bellwether Stocks Movement  ·  10-27
Moderna CEO Seeks to Reassure Investors on Cancer Vaccine’s Wider Potential
Moderna CEO Says Its Cancer Vaccine Isn't a Disappointment, It's a Blockbuster
Dow Jones  ·  10-27
Moderna CEO Says Its Cancer Vaccine Isn't a Disappointment, It's a Blockbuster
U.S. Stocks on the MOVE-Roper, Corcept, Moderna
Reuters  ·  10-26
U.S. Stocks on the MOVE-Roper, Corcept, Moderna
Moderna's Cancer Vaccine Rally Hits a Wall. This Other Drugmaker Stole the Show.
Dow Jones  ·  10-26
Moderna's Cancer Vaccine Rally Hits a Wall. This Other Drugmaker Stole the Show.

Introduction

Company Name.
YieldMax MRNA Option Income Strategy ETF
Affiliated Markets:
ARCA
Listing Date:
--
Main Business:
The fund advisor will seek to employ the fund's investment strategy as the fund relates to MRNA regardless of whether there are periods of adverse market, economic, or other conditions and will not seek to take temporary defensive positions during such periods. The fund is non-diversified.
Issue price:
--